Market Research Logo

Healthcare-Associated Infection Testing (HAI) - The "Prevention Effect" on Diagnostic Markets


This report takes a look at both prevention procedures such as sterilization and surface area disinfection and testing such as molecular tests and immunoassays.  Infection control in healthcare facilities deals largely with protecting building occupants from patients with communicable infectious diseases. Infections, which may result from activities and procedures taking place within the facility, have become a cause for great concern. Infection that is acquired during the course of healthcare is known as a nosocomial, or hospital acquired, infection.

What is the size of the market for healthcare infections testing and prevention?  What are the top companies in the market?  What is the expected growth in the future?  The scourge of healthcare-associated infections or hospital acquired infections, or HAIs, is a real concern for healthcare providers.  They stand to lose profit and contribute to negative patient outcomes if they do not control these infections.  This has created market for three types of products, products to prevent, products to test for disease and then treatment products.  This report deals with the first two, and looks how the markets interplay.  

In some European countries, including the United Kingdom, screening for aggressive infections such as MRSA is performed in many hospitals upon admission.

As part of its coverage, this report includes: 

  Markets for HAI Testing and HAI Prevention, 2016-2021 
  Description of Infections 
  Hospital Spending Priorities 
  Cost of HAIs 
  The Basics - About Nosocomial Infections (HAIs) 
  Prevention Segments for Disinfectants, Sterilization and Wide Area Disinfection
  The Prevention Effect
  Testing Segments - Immunoassays, Molecular, Microbiology
 Important Conclusions about the Market

The infection may occur in a postoperative wound or as a complication unrelated to the disease or condition.  The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20, or 5%, of hospitalized patients will contract an HAI. Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions.

 The prevention market consists of technologies and consumables to reduce the risk of infection transmission. These include:
  Heat/steam sterilization systems
  Chemical sterilization systems and consumables
  Radiation sterilization technologies
  Sterilization verification system

The testing market includes the use of diagnostic equipment and consumables to detect infections and determine the best treatment plan. These include:
  Immunoassays
  Microbial identification and sensitivity tests
  Molecular and DNA tests

To prevent infection, all possible measures are taken to create and maintain a therapeutic environment for the patient and healthcare workers.

In recent years, there have been improved methods for testing infected patients. For example, testing for MRSA infections can be done via a nostril swab, now an effective option in detecting bacteria. Admission screening has been effective in some areas and has reduced the spread of MRSA infections in hospitals in the United States and some European countries.


  • Executive Summary - The Prevention Effect
    • Overview
    • Hospital Spending Priorities
      • Table Hospital Budgets for Sanitation and Infection Control Small in Comparison to other Departments/Areas
    • Cost of HAIs
      • Table HAI Costs per Patient Stay
    • The Basics - About Nosocomial Infections (HAIs)
      • Table Frequency of the Most Common Nosocomial Infections
    • Market Scope
    • Research Methodology
    • Testing Market, Including the Impact of Prevention
      • Table HAI Testing Market Compared to HAI Prevention Market, 2010 -2021
    • Conclusions
  • Introduction and Industry Trends
    • What Infections are Considered HAIs?
    • Description of Infections
      • Acinetobacter Baumannii
      • Clostridium Difficile
      • Gastroenteritis
      • Hospital-Acquired Pneumonia (HAP)
      • Pseudomonas Aeruginosa
      • Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus
      • Stenotrophomonas Maltophilia
      • Tuberculosis
      • Urinary Tract Infections
      • Vancomycin-Resistant Enterococcus
      • Ventilator-Associated Pneumonia (VAP)
      • Patient Risk Factors
      • General Populations at Risk for Infection
        • Table Global Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region
    • World Demographics
      • Table The Global Population, 2005-2050 (in millions)
      • Table Global Population Trends Age 65+, 2000-2050
      • Assessing the Problem: Nosocomial Infection Statistics
        • Table U.S. Hospital Admissions and Percent of Healthcare-associated Infections (HAIs)
        • Table European Union Hospital Admissions and Percent of Healthcare-associated Infections (HAIs)
      • Hospital Length of Stay
    • U.S. Government's National Plan to Prevent Healthcare Associated Infections (HAIs)
    • Steering Committee
    • Epidemiology and Laboratory Capacity for Infectious Diseases
    • Affordable Care Act (ACA) Funding
    • Emerging Infections Program
      • Table U.S. States ACA HAI Prevention Infrastructure Funding Awards, 2013-2016
    • The Department of Health and Human Services: 2017 Budget Highlights
      • Table U.S. Department of Health & Human Services Fiscal Budget, 2015-2017 ($millions)
    • National Healthcare Safety Network
      • Table U.S. Healthcare-associated Infection Standardized Infection Ratio (SIR), 2010-2014
      • Table U.S. Healthcare-associated Infection Standardized Infection Ratio (SIR) 2012 through 2014: MRSA, CLABSI, and CAUTI Infections Down; SSI and C. Diff Infections Up
    • Healthcare Infection Surveillance Process
    • Pharmaceutical Manufacturer and Marketer Trends
      • Trends in Partnerships and Alliances
      • Developers Trends
  • Infection Prevention
    • Overview of Prevention Tactics
    • Market Overview
      • Table The Global Market for Hospital Infection Prevention Equipment and Consumables (Sterilization/Disinfection), 2010-2021
      • Healthcare Infection Prevention Market by Geographical Region
        • Table The Global Market for Hospital Infection Prevention (Sterilization/Disinfection) Estimated Products Sales by Primary Geographic Region, 2010-2021
      • Methods of Transmission -Airborne
      • Methods of Transmission - Contact
      • Methods of Transmission -Droplet
      • Methods of Transmission -Vehicle
    • High-Risk Facilities or Departments
      • Acute Care Hospitals
      • Intensive Care Units
      • Emergency Departments
      • Burn Units
      • Long-term Care Facilities
      • Outpatient Settings
      • Dialysis Centers
      • Technology Overview
        • Table Market Value for Infection Prevention Equipment and Related Consumables by Product Type, 2016
      • Wide Area Disinfection Methods
      • Software for Infection Detection and Control
      • Antiseptic-Coated Catheters
      • UV-C Reflective Coatings
      • Specialized Disinfection/Sterilization Systems
      • Sterilization vs. Disinfection
      • Sterilization
      • Disinfection
    • Equipment and Solutions
      • Table Market Value for Infection Prevention Equipment and Related Consumables by Technology, 2016
    • Heat/Steam Sterilization
      • Product Examples -Advanced Sterilization Products
      • Product Examples - Belimed
      • Product Examples - Getinge
      • Product Examples - Steris Corporation
    • Chemical and Gas Sterilization
      • Disinfecting Agents and Medical Device Components
      • Sterilants
        • Table Summary of Advantages and Disadvantages of Chemical Agents Used as Chemical Sterilants or as High-Level Disinfectants
        • Table Comparison of the Characteristics of Selected Chemicals Used as High-Level Disinfectants or Chemical Sterilants
      • Product Examples - Advanced Sterilization Products
      • Product Examples - Bioquell
      • Product Examples - Getinge
      • Product Examples - Steris Corporation
      • Mid-Level Disinfectants
        • Table Comparison of the Characteristics of Selected Hospital Disinfectants for General Disinfection of Environmental Surfaces
    • Radiation Sterilization
      • Product Examples -Steriliz LLC
      • Product Examples - Steris Corporation
      • Product Examples - UltraViolet Devices, Inc.
      • Product Examples - Xenex Healthcare Services
      • Product Examples - Sterilization and Disinfection Verification and Monitoring Systems
        • Table Developments, Healthcare Infection Prevention
    • Competitive Analysis
      • Table The Global Market for Hospital Infection Prevention (Sterilization/Disinfection), Leading Suppliers' Shares, Estimates for 2016
  • Infection Testing
    • Overview
    • Total Market Size and Forecast
      • Table The Global Market for Hospital Infection Testing/Diagnostics, 2010-2021
      • Healthcare Infection Testing Market by Geographical Region
        • Table The Global Market for Hospital Infection Testing/Diagnostics, Estimated Products Sales by Primary Geographic Region, 2010-2021
    • Testing for Nosocomial Infections
      • Drug-Resistance/Susceptibility Testing
      • Genotypic Methods
      • DNA Sequencing
      • Solid-phase Hybridization Techniques
      • Microarrays
      • Real-time Polymerase Chain Reaction Techniques
      • Phenotypic Methods
      • Phage-based Assays
      • Colorimetric Methods
      • The Nitrate Reductase Assay
      • Chromogenic Testing
        • Table Market Value for Nosocomial Infection Diagnostics by Class, 2016
    • Specific Serious Healthcare Infection Testing
      • Table Tested Samples, Pathogens Isolated by Infection Type
      • Acinetobacter Baumannii
      • Carbapenem-resistant Enterobacteriaceae
      • Clostridium Difficile
      • Product Examples
      • Hospital-Acquired Pneumonia
      • Pseudomonas Aeruginosa
      • Staphylococcus Aureus
      • Methicillin-resistant Staphylococcus Aureus (MRSA)
      • Vancomycin-Intermediate/Resistant Staphylococcus Aureus (VISA/VRSA)
      • Products -AdvanDx, Inc. (OpGen)
      • Products - Becton, Dickinson
      • Products - Cepheid
      • Products - Luminex Corporation
      • Products -Quest
      • Products - Roche
      • Products - Tuberculosis
      • Product Examples and Developments
      • Products - Urinary Tract Infections
      • Vancomycin-resistant Enterococcus
      • Ventilator-Associated Pneumonia
        • Table Significant Approvals for Detecting Serious Healthcare Infections
    • HAI Prevention and Testing Competitive Analysis
      • 3M
      • Abbott Laboratories
      • Advanced Sterilization Products
      • Alere
      • Becton, Dickinson and Company
      • Belimed
      • bioMérieux S.A.
      • Cantel Medical Corp.
      • Danaher
      • Getinge Group
      • Roche
      • Steris plc
      • TSO3, Inc.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report